- Home
- MESO vs MLNK Comparison
MESO vs MLNK Comparison
Compare MESO & MLNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- MLNK
- Stock Information
- Founded
- MESO 2004
- MLNK 1998
- Country
- MESO Australia
- MLNK United States
- Employees
- MESO N/A
- MLNK N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- MLNK Computer Software: Prepackaged Software
- Sector
- MESO Health Care
- MLNK Technology
- Exchange
- MESO Nasdaq
- MLNK Nasdaq
- Market Cap
- MESO 1.3B
- MLNK 1.3B
- IPO Year
- MESO N/A
- MLNK 2021
- Fundamental
- Price
- MESO $15.17
- MLNK $15.57
- Analyst Decision
- MESO Buy
- MLNK Hold
- Analyst Count
- MESO 4
- MLNK 7
- Target Price
- MESO $18.00
- MLNK $20.64
- AVG Volume (30 Days)
- MESO 314.4K
- MLNK 217.7K
- Earning Date
- MESO 08-28-2025
- MLNK 08-11-2025
- Dividend Yield
- MESO N/A
- MLNK N/A
- EPS Growth
- MESO N/A
- MLNK N/A
- EPS
- MESO N/A
- MLNK N/A
- Revenue
- MESO $5,670,000.00
- MLNK $319,970,000.00
- Revenue This Year
- MESO $177.23
- MLNK $6.21
- Revenue Next Year
- MESO $314.04
- MLNK $5.66
- P/E Ratio
- MESO N/A
- MLNK N/A
- Revenue Growth
- MESO N/A
- MLNK 5.15
- 52 Week Low
- MESO $5.78
- MLNK $15.49
- 52 Week High
- MESO $22.00
- MLNK $25.33
- Technical
- Relative Strength Index (RSI)
- MESO 60.94
- MLNK 35.30
- Support Level
- MESO $14.45
- MLNK $16.27
- Resistance Level
- MESO $16.23
- MLNK $17.01
- Average True Range (ATR)
- MESO 0.57
- MLNK 0.37
- MACD
- MESO 0.10
- MLNK -0.07
- Stochastic Oscillator
- MESO 63.12
- MLNK 0.69
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.